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Editors’ NotesSpotlight on HSCs
This month we turn the spotlight on hematopoietic stem cells (HSCs), with reviews and research articles on their role in the develop-
ment and regenerative capacity of blood and potential clinical application. Dick and colleagues review 2 decades of work on themolecular regulation and therapeutic application of human HSCs, and discuss
what we can learn from comparing mouse and humanized models. A review from
McCune and colleagues describes the current state of HSC-based gene therapy
for HIV disease, a potentially curative approach that introduces infection-resistant
HSCs to repopulate the hematopoietic system. Much of the therapeutic potential
of HSCs depends upon their efficient expansion ex vivo, and in this issue a minire-
view from Migliaccio and colleagues describes recent progress in producing red
blood cells from stem cells in vitro for use in transfusions, while two research papers
offer insight into mechanisms for HSC expansion. Zandstra and colleagues
describe a strategy to increase the number of HSCs in an in vitro culture from human
cord blood cells by reducing the levels of paracrine signaling factors—secreted from
maturing hematopoietic cells—that inhibit stem cell self-renewal (see the In Trans-
lation by Bernstein as well). Also in this issue, Crosier and colleagues provide new
mechanistic insight into recent findings that inflammatory stress can have a prolifer-
ative effect on the HSC compartment. In a zebrafish model, the authors show that
inflammation-dependent HSC proliferation requires the cytokine-inducible form of
nitric oxide synthase (iNOS/NOS2), Nos2a, which acts downstream of the transcrip-
tion factor C/ebpb (see the Preview by Herbomel).Profiling Cancer
Targeting stem-cell-like populations within tumors could be a powerful
therapeutic approach, but it also presents a challenge: identifying these
cells within the heterogeneous tumor environment. Here, Wahl and
colleagues perform gene-expression profiling of fetal mammary stem
cells—because the invasive and proliferative processes of mammogene-
sis resemble phases of cancer progression—and find significant overlap
in the expression profile of these stem cells and certain breast cancer
subtypes, suggesting potential therapeutic targets. Also in this issue,
Gibbs and colleagues offer some resolution for conflicting reports as to
the identity of cancer stem cells (CSCs) in acute myeloid leukemia
(AML).Using theH9MmodelofAML, theauthorsdescribemultiple,pheno-
typically distinct tumor-initiating cells, but with overlapping enrichment of
leukemic- andHSPC-associated gene signatures, signaling networks and
survival determinants (see the Preview by Karlsson). The results suggest
that the ability to initiate disease ismorea dynamic cell state thanadefined
phenotype, which offers a possible explanation for previous differences
in interpretation regarding CSC identity as well as mechanistic insight as
to how to effectively target tumor-initiating cells therapeutically.Sealing Cell Fate
Cell fate decisions are impacted by both intrinsic and extrinsic factors. Leukemia inhibitory
factor (LIF) and bone morphogenetic protein (BMP) are extrinsic factors known to work
collaboratively to regulate ESC fate determination, but the mechanism has been unclear.
Here, Chen and colleagues show that downstream signaling from both of these factors
converges upon ERK, a kinase involved in growth and differentiation. LIF activates ERK,
while BMP inhibits ERK by inducing dual specificity phosphatase 9 (DUSP9), an ERK-
specific phosphatase. Intrinsic factors regulating cell fate include the polycomb repressor
complexes (PRC), which promote pluripotency by silencing developmental regulator
genes through histone modification. Some genes exhibit chromatin bivalency, however,
with both repressive and active histone marks. The frequency with which this occurs is
unknown, as is the mechanism by which these competing machineries—to repress or
activate gene transcription—might interact. In this issue, Pombo and colleagues use
molecular, cellular, and genomic analyses to identify sites of chromatin bivalency in
ESCs. They show that repressed PRC gene targets are also bound by unproductive
RNA polymerase II (RNAPII); yet, a second cohort of PRC target genes can be associated
with elongating RNAPII and produce mRNA and protein. Interestingly, many of the genes
in this active cohort are involved in metabolic processes and signaling pathways that are
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